The Recommendation Paradox: Perspectives on Genetic Testing in Huntington's Disease Families Authors: Noit Inbar, Achinoam Socher, Aya Bar David, Penina Ponger, Nurit Omer, Adi Reches, Yael Manor, Tanya Gurevich Published: 2026 ABSTRACT ABSTRACTHuntington's disease (HD) families face complex decisions about predictive genetic testing and reproductive options, including preimplantation genetic testing (PGT), and particularly PGT for Monogenic Disorders (PGT‐M). We examined attitudes toward genetic testing and reproductive options across affected groups within HD families (e.g., people with HD, spouse/caregivers, and at‐risk family members), in a healthcare system with full funding for genetic services. We conducted semi‐structured interviews with 51 participants (17 people with HD, 20 at‐risk relatives, 14 spouses/partners), recruited from the National HD Clinic in Tel Aviv, Israel. Framework Analysis was employed to enable systematic comparison across groups. Three themes emerged from the analysis: “Surprised by HD” revealed that family members were often unaware of genetic risk despite predictable inheritance, reflecting patterns of nondisclosure and misdiagnosis; “Truth or luck” captured divergent attitudes toward predictive testing, with some participants advocating for early knowledge while others emphasized the psychological burden of knowing in the absence of a cure. Together, these themes formed the context for a central finding: “The recommendation paradox”, a striking pattern where individuals who avoided or regretted personal predictive testing nonetheless strongly endorsed reproductive options for offspring, a tension that manifested differently across groups depending on their relationship to HD. The recommendation paradox reveals ethical tensions between reproductive autonomy and emerging expectations of genetic responsibility. This pattern persists even when economic barriers are removed, demonstrating that psychological factors remain primary determinants of testing uptake. Genetic counseling should explicitly address divergent attitudes toward personal versus offspring testing, recognizing that support for prevention does not necessarily indicate readiness for personal testing. Families affected by Huntington's disease (HD) face profound psychological challenges when navigating reproductive decisions under the shadow of genetic uncertainty. The knowledge that each child has a 50% chance of inheriting this fatal neurodegenerative disorder creates complex emotional and ethical dilemmas for at‐risk individuals, their partners, and extended families (Fahy et al. 2023; Roberts et al. 2020). Reproductive choices are often made during peak reproductive years (typically ages 25–40), sometimes preceding the typical age of HD symptom onset (30–50 years). While at‐risk individuals can elect predictive testing to inform reproductive decisions, many choose to preserve uncertainty about their own status (Anderson et al. 2019; Tillerås et al. 2020), making reproductive planning decisions without definitive knowledge of whether they carry the HD mutation. The psychological burden of potentially transmitting a devastating disease to one's children, combined with witnessing the progressive decline of affected family members, creates cascading dilemmas that ripple through multiple generations (Kjoelaas et al. 2022; Cooper et al. 2024; Taylor‐Sands and Bowman‐Smart 2022; Furby et al. 2022). Despite advances in predictive testing and reproductive technologies, many at‐risk individuals struggle with profound ambivalence, wanting to prevent transmission while simultaneously preserving hope, maintaining family relationships, and managing their own psychological well‐being (Tillerås et al. 2020; Wieringa et al. 2022). HD is caused by an expanded CAG repeat in the huntingtin gene, with full penetrance occurring at 40 or more repeats (Geraedts 2021). The autosomal dominant inheritance pattern means that affected individuals have a 50% chance of passing the mutation to each child, creating what Pierron et al. (2021) describe as evolving attitudes toward genetic responsibility across generations. Predictive genetic testing has been available since 1993, allowing at‐risk individuals to determine their genetic status before symptom onset. However, uptake remains remarkably low at approximately 5%–20% globally (Anderson et al. 2019; Piña‐Aguilar et al. 2019), reflecting psychological factors that influence testing decisions, including the choice to preserve uncertainty rather than face potential genetic confirmation (Tillerås et al. 2020). Over the years, with the emergence of reproductive technologies, HD at‐risk individuals have several options to manage genetic risk in family planning decisions. Prenatal testing methods, including Chorionic Villus Sampling (CVS) and Amniocentesis, can determine fetal HD status during pregnancy, though this necessitates difficult decisions about pregnancy continuation (Bouchghoul et al. 2016). Preimplantation Genetic Testing (PGT) has been offered as an alternative approach that tests embryos before implantation, allowing couples to avoid the emotional burden of terminating an affected pregnancy (Christensen et al. 2022; Geraedts 2021). Preimplantation Genetic Testing for Monogenic/Single Gene Defects (PGT‐M), formerly known as Preimplantation Genetic Diagnosis (PGD), is a process of (a) embryo creation through IVF; (b) embryo biopsy, typically on the fifth or sixth day of embryo development (blastocyst stage); (c) genetic analysis, where the biopsied cells are analyzed for the specific HTT genetic mutation; (d) embryo selection and transfer, where embryos not carrying the genetic mutation are prioritized for transfer to the uterus. For individuals who wish to prevent HD transmission while preserving uncertainty about their own status, nondisclosure PGT or exclusion testing can be offered. In nondisclosure PGT, the embryo is tested for HD mutation without revealing the at‐risk parent's own carrier status. Exclusion testing uses linked genetic markers rather than direct mutation analysis, avoiding any inference about parental status, and is generally preferred over nondisclosure approaches (ESHRE PGT Consortium Steering Committee 2020). Each option carries distinct psychological implications (de Die‐Smulders et al. 2013; Van Rij et al. 2014). Despite HD being one of the most common indications for PGT‐M globally, the gap between those who could benefit and those accessing it remains substantial. Of the approximately 100,000–200,000 individuals at 50% risk in Europe and North America, only 1%–3% pursue preimplantation or prenatal testing options (Van Rij et al. 2014; Piña‐Aguilar et al. 2019). The low uptake reflects various barriers including personal, ethical, and religious objections to embryo selection (Valdés 2023); concerns about IVF procedures; financial constraints in some healthcare systems (Kemper et al. 2019), where the cost of the process can range from $7000 to $12,000 per cycle; and psychological factors including denial, hope for future cures, and fear of discovering one's own status through offspring testing (Fahy et al. 2023). The relatively modest success rates of PGT‐M per cycle represent an additional practical barrier: because HD follows autosomal dominant inheritance, approximately 50% of embryos will carry the mutation and be unavailable for transfer, further limiting the chances of a successful outcome (Geraedts 2021). Understanding noneconomic barriers, such as psychological and social barriers, is particularly relevant as other healthcare systems consider expanding coverage. However, the gap between expressed interest in reproductive options and actual utilization is not a recent phenomenon. As early as 1987, before direct HD testing was available, Kessler et al. found that 67% of at‐risk individuals stated they would consider prenatal testing via linkage analysis, and 70% of those indicated they would terminate an affected pregnancy. Yet, when these options became clinically available, uptake remained substantially lower than these theoretical preferences suggested. This pattern, which Schulman and Stern (2015) later termed “future discounting of genetic risk”, reflects a consistent tendency for at‐risk individuals to express strong support for reproductive interventions in principle while demonstrating reluctance to pursue them in practice. This discrepancy has persisted across technological advances: from linkage testing (available since 1986) to direct mutation testing (1993), to contemporary reproductive options. Despite evolving technologies and, in some contexts, removal of financial barriers, the psychological gap between intention and action remains a defining feature of reproductive decision‐making in HD families. Understanding this persistent gap requires consideration of multiple perspectives within affected families. Recent qualitative work has illuminated the complex psychological landscape of different affected groups: Cooper et al. (2025) explored how at‐risk individuals manage wellbeing while living with uncertainty, navigating between “HD and non‐HD worlds” with heightened temporal awareness; Carney et al. (2025) examined caregiver burden and isolation; Wieringa et al. (2022) investigated premanifest individuals' experiences of living “in limbo” between genetic knowledge and symptom onset; and Muñoz‐Ortega et al. (2025) highlighted the challenges of aging with genetic uncertainty. Bouchghoul et al. (2016) found that couples who underwent prenatal testing often made decisions based on personal HD experiences and ethical beliefs about preventing suffering. These diverse perspectives suggest that reproductive decision‐making in HD is shaped not only by individual psychological factors but also by one's position within the family system and relationship to the disease. In this study, we aimed to explore perceptions, beliefs, and experiences regarding reproductive options and genetic testing among multiple affected individuals within HD families in a fully funded healthcare system. Israel provides comprehensive coverage for both genetic testing and reproductive options including prenatal testing and PGT, offering a unique context to examine psychological and cultural factors when most economic constraints are eliminated. By including people with HD, at‐risk relatives, and spouses, we sought to understand how different positions within the family system shape reproductive recommendations and reveal potential paradoxes between personal choices and advice for others. Methods This qualitative study employed Framework Analysis (Gale et al. 2013), a systematic method designed for comparative analysis across defined groups. While Interpretative Phenomenological Analysis (IPA) has been effectively used in HD research to explore lived experiences of caregivers and premanifest individuals (Carney et al. 2025), Framework Analysis was specifically chosen for this study for several reasons. First, our research question explicitly sought to understand and compare attitudes toward genetic and prenatal testing across three distinct groups: people with Huntington's disease, at‐risk relatives, and healthy spouses/partners. Second, the method's matrix structure enabled transparent tracking of both divergent and convergent perspectives across these groups while maintaining connection to individual participants' contexts. Third, this approach aligns with our interpretivist paradigm (Willis 2007) while offering a structured analytical framework that facilitates both within‐case and cross‐case analysis, essential for understanding how different positions within the HD family system shape reproductive decision‐making. This approach is grounded in the recognition that experiences and attitudes toward RDM are shaped by individuals' positions within the family system, their relationship to HD, and lived experiences with genetic risk. This epistemological stance acknowledges that participants construct meaning from their unique vantage points: whether as someone living with HD, at‐risk for inheriting the condition, or caring for an affected family member, and that these perspectives may converge or diverge in meaningful ways. Human Studies and Informed Consent This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Institutional Review Board of Tel Aviv Sourasky Medical Center (IRB approval number: 0614‐18). Written informed consent was obtained from all participants prior to their inclusion in the study. No identifying information is included in the manuscript. Between 2020 and 2024, during routine clinic visits, individuals with HD and their family members were invited to participate in the study. Those expressing interest received detailed written information about the study's purpose, procedures, and confidentiality measures. After providing written informed consent, participants were contacted to schedule an interview with the first author. The first author is a physiotherapist with over 15 years of experience at the National HD Center in Israel and completed a fellowship with the European Huntington's Disease Network (EHDN) at Cardiff HD Center. The first author completed doctoral research on moral distress using mixed methods, providing theoretical grounding in ethical decision‐making frameworks. This combined clinical and ethical research background facilitated exploration of tensions between personal autonomy, family responsibility, and reproductive choices. As an insider researcher already known to some participants through clinical care, the first author recognized that established relationships fostered trust and willingness to share sensitive experiences. However, this dual clinical‐researcher role required heightened reflexivity to distinguish clinical knowledge from participants' lived experiences and remain open to perspectives challenging clinical and ethical assumptions. Regular discussions with the multidisciplinary author team, including those without direct HD clinical experience, provided critical distance throughout analysis. Semi‐structured interviews lasting 45–115 min (mean 60 min) were conducted. The interview guide (available from corresponding author) included open‐ended questions exploring different angles: discovery of family HD history; knowledge of reproductive options; attitudes toward genetic testing (advantages, disadvantages, personal decisions); experiences with reproductive decision‐making; and perspectives on recommendations for at‐risk family members. Questions addressed both prenatal testing and preimplantation options. Examples included: How did you learn about HD and your relation to it?To your knowledge, what are the options for ensuring healthy offspring for people from HD families?In your opinion, what are the advantages and disadvantages of prenatal testing?Have you undergone genetic testing yourself? Could you elaborate on your considerations?In some fertility centers, there is an option to perform a process whereby, before pregnancy, it is verified that the embryo is not a carrier of HD. In your opinion, what are the advantages and disadvantages of such a process? How did you learn about HD and your relation to it? How did you learn about HD and your relation to it? To your knowledge, what are the options for ensuring healthy offspring for people from HD families? To your knowledge, what are the options for ensuring healthy offspring for people from HD families? In your opinion, what are the advantages and disadvantages of prenatal testing? In your opinion, what are the advantages and disadvantages of prenatal testing? Have you undergone genetic testing yourself? Could you elaborate on your considerations? Have you undergone genetic testing yourself? Could you elaborate on your considerations? In some fertility centers, there is an option to perform a process whereby, before pregnancy, it is verified that the embryo is not a carrier of HD. In your opinion, what are the advantages and disadvantages of such a process? In some fertility centers, there is an option to perform a process whereby, before pregnancy, it is verified that the embryo is not a carrier of HD. In your opinion, what are the advantages and disadvantages of such a process? Follow‐up probes explored participants' reasoning and emotional responses in depth. The interviewer used reflective listening, allowed silence for participant reflection, and avoided leading questions that might suggest “correct” reproductive choices. Interviews were conducted either in‐person or by telephone based on participant preference. Following previous research demonstrating that telephone interviews facilitate disclosure of sensitive information and provide convenience for hard‐to‐access populations (Johnson et al. 2021; Kjoelaas et al. 2022; Trier‐Bieniek 2012), telephone interviews were offered as an option. Participants ensured they had a quiet, private environment. Despite the absence of visual cues, telephone interviews yielded rich, in‐depth data as participants openly shared personal, emotional experiences about family secrets, genetic risk, and reproductive decisions. Before and during the interview, information or definitions and medical terms were not given to the interviewees, allowing assessment of naturalistic understanding. Participants did not demonstrate significant misconceptions (e.g., believing HD could not be inherited). The interviewer avoided correcting minor knowledge gaps during the interview itself to preserve the authenticity of participants' perspectives. Sample size was determined by the principle of information power (Malterud et al. 2016): Given our focused research aim, the high specificity of participants recruited from a specialist HD clinic, the use of an established theoretical framework, the researcher's extensive clinical experience with this population, and a cross‐case analysis strategy, a sample of 51 participants was considered sufficient. This was confirmed through team discussion when the final three interviews did not produce new codes or conceptual insights. Data Analysis Analysis proceeded through seven stages: Transcription All 51 interviews were audio‐recorded and transcribed in Hebrew, capturing participants' exact words. Transcriptions also included contextual notes documenting emotional expressions (e.g., crying, pauses, enthusiastic speech) to preserve the affective dimension of participants' experiences. Familiarization With the Interview As each interview was completed and transcribed, the first author read it repeatedly to develop familiarity with the content, noting initial. Impressions and recurring ideas in analytical memos. This early immersion informed the interview approach with subsequent participants while ensuring each interview remained participant driven. During familiarization, broad areas of interest were noted, including: family communication patterns about HD, attitudes toward knowing versus not knowing genetic status, tensions between personal autonomy and family responsibility, and apparent differences in how PWHD, at‐risk relatives, and caregivers discussed reproductive decisions. Coding The first author conducted systematic line‐by‐line open coding on all 51 transcripts, highlighting words, phrases, and ideas that related to the research question: What are the attitudes of people coping with HD toward prenatal testing and genetic testing? This initial coding identified meaning units capturing participants' beliefs, emotions, experiences, and recommendations regarding RDM and genetic testing. Open coding generated preliminary codes, such as: “Family kept HD secret”; “Found out by accident”; “Fear of knowing brings more harm than good”; “Need to know early to prepare”; “Responsibility to prevent HD in next generation”; “Support PGT‐M but won't test myself”; “Living with uncertainty is preferable”; “Insurance discrimination concerns”; “No cure, so why know?” etc. To enhance trustworthiness, detailed coding memos documented emerging patterns and questions, and preliminary codes were discussed with coauthors. Developing a Working Analytical Framework Preliminary codes were iteratively organized into categories based on conceptual similarities and shared meaning. Codes were grouped into broader categories representing key dimensions of participants' experiences. For example, codes related to “family kept HD secret,” “found out by accident,” and “misdiagnosed as other diseases” were grouped into a category provisionally labeled “Unexpected discovery of family HD history.” The framework was developed with explicit attention to the comparative dimension: we systematically attended to potential differences and commonalities across groups (PWHD, at‐risk relatives, spouse/partners). Categories were organized into a tree diagram structure, clearly defined, and iteratively refined through team discussion. Applying the Analytical Framework (Indexing) Once the working analytical framework stabilized, it was systematically applied to the entire dataset through indexing, tagging relevant passages in each transcript according to the category framework. Indexing remained iterative; when new dimensions emerged from later transcripts, earlier transcripts were revisited to ensure consistent application. Charting Data Into the Framework Matrix When the complete dataset was ready, we created summary charts lifting relevant data from individual transcripts. Charting involved summarizing data by category for each participant while preserving the original meanings and participants' own expressions, a process which required balancing data reduction with retention of context and emotion in participants' words. With data organized, we systematically compared across groups, explicitly examining: Commonalities—Shared attitudes, beliefs, or experiences across all groups; Unique differences—Perspectives or concerns specific to each group; Differences in life views and worldviews—We paid particular attention to how living with/being at‐risk for a severe adult‐onset genetic disease shaped fundamental perspectives on knowledge, control, responsibility, fate, and quality of life; Perceptions of family planning—How each group conceptualized reproductive decision‐making, balancing desires for children against genetic risks, and weighing personal autonomy against responsibility to future generations. During charting and comparison, a striking pattern emerged: participants who expressed ambivalence about personal predictive testing nonetheless strongly advocated for PGT‐M for future generations. To systematically understand this paradox across groups, we developed an additional comparative analytical framework (detailed in the results—Table 2). Interpreting the Data The final analytic stage moved beyond descriptive summary to interpretation of patterns within and across categories. Interpretive concepts that describe or explain aspects of the data and represent the final output of the Framework Analysis were identified (Gale et al. 2013), and three overarching themes were constructed. Themes were developed by interrogating multiple categories from the analytical framework. Each theme was defined with clear conceptual boundaries, grounded in multiple categories, supported by representative quotes from diverse participants, validated by returning to original transcripts, and refined through iterative team discussions. Translation from Hebrew to English was performed by the first author (native Hebrew speaker) with assistance from an AI language model (Claude, Anthropic) to ensure accurate English expression while preserving Hebrew idiomatic meanings and cultural nuances. Representative quotes were selected first in Hebrew based on conceptual richness, then carefully translated to maintain fidelity to participants' intended meanings. Several strategies enhanced credibility and dependability, to assure trustworthiness: Detailed documentation tracked analytical decisions from initial codes through categories to final themes (audit Trail); While the first author conducted primary coding and indexing, preliminary categories and interpretive themes were regularly discussed with co‐authors, to challenge assumptions in particular; The Framework Method's structured approach enabled transparent comparison across groups (systematic comparison); Thick Description via quotes allows readers to assess fit between data and interpretations; The first author maintained awareness of how clinical HD experience might influence interpretation through bracketing and reflexive memos; Concurrent data collection and analysis allowed ongoing assessment until reaching saturation. Results The study included 51 participants, consisting of 35 women (68.6%) and 16 men (31.4%). Among the participants, 17 (33.3%) were individuals diagnosed with Huntington's disease (PWHD); 20 at‐risk relatives (6 siblings—11.8%, 8 children—15.7%, 6 parents—11.8%) and 14 spouses/partners (27.5%), who are not at risk but serve as primary caregivers. Some at‐risk relatives also provided care for affected family members, reflecting the overlapping nature of these roles within HD families. Age ranged from 19 to 73 years, with a mean of 46.5 (SD 15.4). Racial and ethnic data were not systematically collected; most participants were Israeli Ashkenazi Jews, reflecting the population served by the National HD Center (Zitser et al. 2017). All 17 participants with HD were symptomatic (manifest HD), treated regularly at the center. CAG repeat length was not documented in this study. Some participants received a clinical diagnosis without formal genetic testing, itself reflecting a pattern of genetic uncertainty. The diverse sample provided a comprehensive representation of the experiences and perspectives of both individuals directly affected by HD and their family members (Table 1). TABLE 1Participant demographic characteristics by family member group.CharacteristicPWHD (n = 17)At‐risk relatives (n = 20)Spouses/Partners (n = 14)Total (n = 51)GenderFemale, n (%)9 (52.9%)16 (80.0%)10 (71.4%)35 (68.6%)Male, n (%)8 (47.1%)4 (20.0%)4 (28.6%)16 (31.4%)Age (years)Mean (SD)43.2 (11.7)43.4 (18.2)55.1 (12.4)46.5 (15.4)Range29–6719–7134–7319–73Years of educationMean (SD)13.5 (2.3)13.3 (2.4)12.6 (3.0)13.2 (2.5)Range10–1810–187–187–18Marital statusMarried, n (%)8 (47.1%)11 (55.0%)14 (100%)33 (64.7%)Single, n (%)4 (23.5%)5 (25.0%)0 (0%)9 (17.6%)Divorced/Widowed, n (%)5 (29.4%)4 (20.0%)0 (0%)9 (17.6%)Parenting statusHas children, n (%)12 (70.6%)13 (65.0%)14 (100%)39 (76.5%)Does not have children, n (%)5 (29.4%)7 (35.0%)0 (0%)12 (23.5%)Range (among parents)1–41–31–51–5 Note: At‐risk relatives include siblings and adult children (> 18 years of age). Spouses/caregivers are not genetically at risk. Percentages may not sum to 100% due to rounding.Abbreviation: PWHD, People with Huntington's Disease. Participant demographic characteristics by family member group. Note: At‐risk relatives include siblings and adult children (> 18 years of age). Spouses/caregivers are not genetically at risk. Percentages may not sum to 100% due to rounding. Abbreviation: PWHD, People with Huntington's Disease. Framework Analysis revealed three overarching themes, and comparison across groups revealed both commonalities and group‐specific perspectives (particularly evident in Theme 3). We also identified patterns transcending group categories, suggesting shared experiences across the HD‐affected family system. The following sections provide detailed examples for each theme, allowing for an in‐depth understanding of the participants' experiences and perspectives. Theme 1: “Surprised by HD” Participants recalled their first understanding of being an HD‐family member as unexpected, either hidden or misunderstood. For example, this participant shared her experience of discovering her family's HD history:I found out ‐ my sister got tested at the age of 20 when our father passed away. When my father was ill, they didn't say it was Huntington's. In the family, they told us it was Parkinson's or dementia. Until now, they say it's not Huntington's, and his sister said it doesn't pass from father to daughter. (16, Relative ‐ sister) I found out ‐ my sister got tested at the age of 20 when our father passed away. When my father was ill, they didn't say it was Huntington's. In the family, they told us it was Parkinson's or dementia. Until now, they say it's not Huntington's, and his sister said it doesn't pass from father to daughter. (16, Relative ‐ sister) The true nature of HD was concealed and misinterpreted across generations in this family. The participant's relatives attributed the father's condition to other neurological disorders and held the mistaken belief that HD could not be genetically inherited from father to daughters. Another participant, the spouse of an individual with HD, shared their experience of being unaware of the disease's presence in the family at the time of their marriage:We got married, I didn't know anything. His sister introduced him to me. His mother passed away two years before our wedding. I didn't know that he had sick siblings. Our daughter was already 17 years old when I found out. They didn't want to tell me the truth. They were afraid that I wouldn't marry him. (14, Relative ‐ mother) We got married, I didn't know anything. His sister introduced him to me. His mother passed away two years before our wedding. I didn't know that he had sick siblings. Our daughter was already 17 years old when I found out. They didn't want to tell me the truth. They were afraid that I wouldn't marry him. (14, Relative ‐ mother) This quote further illustrates how HD was hidden from the participant, with the family withholding information about the presence of the disease due to their fear that it would prevent the marriage from taking place. The participant only learned the truth when her daughter was 17 years old, at which point she became aware of the risk their child faced. As the daughter entered her 20s and began exhibiting the first behavioral symptoms of HD, the participant understood the implications of the family secret that had been kept from them. This revelation not only exposed the long‐held family secret but also highlighted the participant's transition from an unknowing spouse to a mother coping with her child's inherited condition. Another participant shared their gradual discovery of their mother's HD diagnosis and the genetic implications of the disease:I saw my mother going to her doctor in Haifa, and I saw a booklet with information about Huntington's. That's how I found out about it […]. I didn't know about genetics. I only understood genetics when my sister wanted to get pregnant and told me about the process she had to go through. (30, PWHD) I saw my mother going to her doctor in Haifa, and I saw a booklet with information about Huntington's. That's how I found out about it […]. I didn't know about genetics. I only understood genetics when my sister wanted to get pregnant and told me about the process she had to go through. (30, PWHD) The participant pieced together the picture gradually: first through a booklet, then through her mother's worsening symptoms, and only fully grasped the genetic implications when her sister began planning a pregnancy. One participant and his wife unexpectedly discovered the presence of HD in her family while trying to understand the cause of her mother's death:My wife wasn't sick yet, she was an athlete. She wanted to find out what happened to her mother, who had been in various mental institutions […]. When we searched for the information, her mother had already passed away. But my wife wanted to know what she died from. That's how we discovered by chance that it was Huntington's. We told the whole family, and there was complete panic. My wife's brother got sick shortly after. It was in 1986. My wife only got sick two years later, with mild signs of balance problems. She was never tested. She just got sick. They (the family) didn't really treat it. They didn't know anything. She lost her job […]. We got divorced. (44, Relative ‐ father) My wife wasn't sick yet, she was an athlete. She wanted to find out what happened to her mother, who had been in various mental institutions […]. When we searched for the information, her mother had already passed away. But my wife wanted to know what she died from. That's how we discovered by chance that it was Huntington's. We told the whole family, and there was complete panic. My wife's brother got sick shortly after. It was in 1986. My wife only got sick two years later, with mild signs of balance problems. She was never tested. She just got sick. They (the family) didn't really treat it. They didn't know anything. She lost her job […]. We got divorced. (44, Relative ‐ father) This example highlights the surprise and panic that ensued when the participant and his wife discovered by chance that her mother had died from HD. It also underscores the potential for undiagnosed, misunderstood, or untreated symptoms to strain relationships and lead to significant life changes, such as job loss and divorce. The experiences shared by participants highlight the emotional and psychological impact of discovering the presence of HD in their family, particularly when this information was unexpectedly revealed or had been withheld for an extended period. One daughter said: “I found out due to the symptoms and diagnosis of my aunt. The aunt asked me to perform genetic tests before pregnancy out of guilt for her children and grandchildren” (2, Relative—daughter), and by that highlighted the secret hidden by some family members, alongside the sense of guilt and responsibility felt by others toward future generations. Theme 2: “Truth or Luck” Participants in the study expressed divergent perspectives regarding their approach to uncovering the truth about their genetic status and its implications for future generations. Two distinct coping strategies emerged: actively seeking the truth or deliberately avoiding it and leaving the future to fate. These two strategies represented fundamentally different ways of dealing with uncertainty. Those in search of their genetic history and current status emphasized their sense of responsibility toward future generations. They felt compelled to uncover the truth about their HD status in order to make informed decisions about family planning and protect their potential offspring from the challenges of HD. In contrast, others were reluctant about HD testing, preferring to leave outcomes to fate while acknowledging the possible ramifications of this choice. These individuals often cited the emotional burden and potential psychological distress associated with knowing their genetic status as reasons for their avoidance of testing, choosing instead to cope with the uncertainty by focusing on living in the present. The main question for this theme was: “In terms of genetic testing, what would you suggest a family member who is at‐risk of HD do?” Those who answered that they would recommend genetic testing said it was important to know the truth early on, to be prepared for the future, and to make informed decisions about family planning. They emphasized the need to stop the disease from affecting future generations and to spare their children from suffering. Here are a few examples:That way they can react faster. It took my mom ten years to realize it was Huntington's. I could have known if I had the gene or not, even before I was sick. I wanted to know for myself and to know what to do for the next generation. It didn't work out, but at least I knew. (1, PWHD) It's better to know in order to prepare for the future. (6, Relative ‐ sister) It's worth knowing the truth… uncertainty takes a lot of unnecessary energy. It's better to know and deal with it. (7, Relative ‐ mother) It's better to know early than never. My mother's illness ‘caught her by surprise’. We didn't know about its existence. It took a long time until we found out what was happening. For me, it's important to be prepared. I don't like surprises of this kind. (42, PWHD) One should know the truth. Not to wonder all your life. If you know in time, you will live more. We need to stay on the positive side. Not to despair. You can adapt to the disease. (21, PWHD) That way they can react faster. It took my mom ten years to realize it was Huntington's. I could have known if I had the gene or not, even before I was sick. I wanted to know for myself and to know what to do for the next generation. It didn't work out, but at least I knew. (1, PWHD) It's better to know in order to prepare for the future. (6, Relative ‐ sister) It's worth knowing the truth… uncertainty takes a lot of unnecessary energy. It's better to know and deal with it. (7, Relative ‐ mother) It's better to know early than never. My mother's illness ‘caught her by surprise’. We didn't know about its existence. It took a long time until we found out what was happening. For me, it's important to be prepared. I don't like surprises of this kind. (42, PWHD) One should know the truth. Not to wonder all your life. If you know in time, you will live more. We need to stay on the positive side. Not to despair. You can adapt to the disease. (21, PWHD) These quotes illustrate the perspective of participants who actively seek the truth about their genetic status. They emphasize the importance of knowing one's HD status in order to react quickly, prepare for the future, and make informed decisions about the next generation. They stress the value of knowing the truth, even if it is difficult, and the need to overcome shame, to deal with the reality of HD. These quotes suggest a strong sense of responsibility toward oneself and future generations, a sub‐theme that was highlighted by the following:Not everyone can go through this process (genetic testing). It takes a few months. It's a meeting with a psychiatrist. With a genetic counselor. It's nerve‐racking. It takes mental strength. It takes a bit of optimism. I had a 75% chance of getting sick! I was tested a week before the start of my studies. I didn't want to fall into it. I kept optimistic. My twin brother was tested and found to be sick… Mentally, I won't survive the knowledge that maybe my child is flawed. I couldn't stand it. I had to get tested and it was a difficult and long process… If a person is strong enough, if they have a support system and a plan ‐ where they will be the day after the answer ‐ all this will affect the decision to get genetically tested or not. (46, Relative – daughter) Not everyone can go through this process (genetic testing). It takes a few months. It's a meeting with a psychiatrist. With a genetic counselor. It's nerve‐racking. It takes mental strength. It takes a bit of optimism. I had a 75% chance of getting sick! I was tested a week before the start of my studies. I didn't want to fall into it. I kept optimistic. My twin brother was tested and found to be sick… Mentally, I won't survive the knowledge that maybe my child is flawed. I couldn't stand it. I had to get tested and it was a difficult and long process… If a person is strong enough, if they have a support system and a plan ‐ where they will be the day after the answer ‐ all this will affect the decision to get genetically tested or not. (46, Relative – daughter) This quote presents a unique perspective, as it comes from a participant who faced a higher risk of inheriting HD due to both of her parents being affected by the disease. Despite the increased likelihood of positive results and the potential emotional burden, this individual chose to confront the truth and undergo genetic testing. This quote highlights the participant's understanding of the challenges associated with genetic testing, including the lengthy process, the involvement of multiple healthcare professionals, and the mental and emotional strength required to cope with the potential outcomes. The participant acknowledges that not everyone may be equipped to handle this process, emphasizing the importance of personal resilience, optimism, and a support system. Despite the high risk of testing positive and the potential emotional toll, this participant chose to undergo testing to determine whether PGT‐M would be necessary. This decision reflects a strong sense of responsibility toward future offspring and a willingness to face the truth, even in the face of rare, heightened risk and uncertainty. On the other hand, those who opposed genetic testing or regretted testing themselves expressed concerns about the emotional and psychological impact of living with the knowledge of a positive result, especially in the absence of a cure for HD. They worried that a positive diagnosis could lead to negative consequences. Some participants emphasized the importance of maintaining a positive outlook and focusing on healthy lifestyle choices, rather than waiting for symptoms to appear. Here are some examples:I wasn't tested. I'm 52 years old, and if I don't have symptoms, I'm not at risk. My father was diagnosed when he was 62. My son was then 8 months old. He (the father) didn't have the usual signs. Mainly cognitive impairment. They thought it was Alzheimer's. Only when my brother was diagnosed did we understand that it was Huntington's. I would tell others that there's no point in getting tested. Just living in fear. (16, Relative – sister) What will it give? Living with knowing? There's no cure, what will it give? I know that some of the patients commit suicide after the diagnosis. What, how to stop such a thing? (28, Relative – spouse) I don't know if there's an advantage to early knowledge as long as there's no cure for the disease. All the insurance policies change if you are diagnosed. If you are healthy ‐ the diagnosis gives peace of mind. If not ‐ it's a lot of trouble and doesn't give anything and even harms your rights. (39, Relative – father & spouse)As long as there's no cure, it will only cause imbalance, uncertainty. A positive result will cause a person to wait for signs (symptoms) every day. Children of affected families must do sports, eat healthy, not smoke, maintain health as much as possible. (43, Relative – spouse) I wasn't tested. I'm 52 years old, and if I don't have symptoms, I'm not at risk. My father was diagnosed when he was 62. My son was then 8 months old. He (the father) didn't have the usual signs. Mainly cognitive impairment. They thought it was Alzheimer's. Only when my brother was diagnosed did we understand that it was Huntington's. I would tell others that there's no point in getting tested. Just living in fear. (16, Relative – sister) What will it give? Living with knowing? There's no cure, what will it give? I know that some of the patients commit suicide after the diagnosis. What, how to stop such a thing? (28, Relative – spouse) I don't know if there's an advantage to early knowledge as long as there's no cure for the disease. All the insurance policies change if you are diagnosed. If you are healthy ‐ the diagnosis gives peace of mind. If not ‐ it's a lot of trouble and doesn't give anything and even harms your rights. (39, Relative – father & spouse) As long as there's no cure, it will only cause imbalance, uncertainty. A positive result will cause a person to wait for signs (symptoms) every day. Children of affected families must do sports, eat healthy, not smoke, maintain health as much as possible. (43, Relative – spouse) These quotes highlight the perspective of participants who are reluctant to pursue genetic testing or do not recommend it to at‐risk family members. They express concerns about living with the knowledge of a positive result, especially in the absence of a cure for HD. Some participants worry that a positive diagnosis could lead to negative consequences, such as changes in insurance policies or even suicide. They emphasize the importance of maintaining a positive outlook and focusing on healthy lifestyle choices, rather than waiting for symptoms to appear. The decision to pursue genetic testing is portrayed as a highly personal one that depends on individual circumstances and coping mechanisms. While some participants see value in early knowledge, others prioritize maintaining a sense of normalcy and avoiding the potential negative consequences of a positive result. The quotes highlight the complex emotional landscape surrounding genetic and prenatal testing for HD and the importance of considering each individual's unique needs and perspectives. Theme 3: “The Recommendation Paradox” While participants discussed various reproductive options throughout interviews, the recommendation paradox emerged most strongly in response to questions specifically addressing preimplantation genetic testing. Participants who expressed ambivalence about personal predictive testing nonetheless strongly and spontaneously endorsed PGT‐M for offspring. This participant‐driven emphasis on PGT‐M, rather than prenatal testing, when discussing offspring prevention explains the specific focus on PGT‐M within this theme. Where participants' responses were not technology‐specific, the broader term ‘reproductive options’ is used. Interestingly, among at‐risk relatives, 13 of 20 had biological children and 7 did not; however, both groups expressed strong support for PGT‐M in principle, suggesting the paradox was not driven solely by parenting experience. Within this theme, analysis revealed that the “recommendation paradox” manifested differently across groups (PWHD, at‐risk individuals, and spouses/partners). To systematically compare these differences, we developed an analytical framework organizing participant perspectives across four dimensions that emerged from comparing responses: (1) Knowledge vs. Uncertainty revealing preferences for knowing genetic status as opposed to living with ambiguity; (2) Personal Choice vs. Family Responsibility, showing the tension between individual autonomy and obligations to future generations; (3) Emotional Burden vs. Practical Benefits, highlighting the weighing of psychological costs against practical advantages of testing; and (4) Current Generation vs. Future Generations, showing differential attitudes toward testing for oneself versus offspring. These dimensions were not predetermined categories but emerged inductively by comparing how PWHD, at‐risk individuals, and caregivers discussed their testing and reproductive decisions. Table 2 presents representative quotes illustrating how each dimension manifests across groups, revealing systematic differences in perspective based on one's relationship to HD. TABLE 2“The Recommendation Paradox” across groups.ParadoxPWHDAt‐RiskCaregiversKnowledge vs. Uncertainty Often advocate for knowledge based on their experience. “It's better to know in order to prepare for the future.” (13) Valuing prevention for offspring in retrospect, while simultaneously choosing not to know their own genetic status “If I were before childbirth, maybe I would do PGT‐M, but I would prefer not to know about myself.” (38) Generally, seek knowledge to aid in planning and care. “Uncertainty consumes a lot of unnecessary energy. It's better to know and treat.” (9) Personal Choice vs. Family Responsibility Often feel a strong responsibility to prevent HD in future generations. “I'm a carrier and I had children through egg donation. If we can stop the disease, that's the most important thing!” (35) May struggle between personal desire not to know and family planning. “It's worth it for those who don't have children to do the test to prevent it for the next generation… For those who already have children—it introduces unnecessary pressure.” (23) Often prioritize family planning and prevention. “To stop the chain! Enough with this disease! To take responsibility for the family, for the children!” (27) Emotional Burden vs. Practical Benefits May emphasize practical benefits based on their experience. “If the result is positive, the person can be aware of the progression of symptoms and follow developments and medications for the disease.” (10) Often most conflicted about the emotional burden of knowing. “What's the benefit? To live with knowing? There's no cure, what will it give? I know that a high percent of patients commit suicide. How can that be stopped?” (24) May focus on practical benefits for care and planning. “When you know there's a disease, and the person is living their life, it's better not to get into stress.” (11) Current Generation vs. Future Generations Strongly support preventive reproductive options for future generations; may have mixed feelings about current generation testing. “I would encourage everyone to receive treatment on time and to have children after genetic testing of the embryo/fetus.” (4) *In Hebrew, the word for fetus and embryo is the same Some support preventive reproductive options for future generations, while others prioritize present emotional wellbeing over future genetic prevention, fearing that testing would harm existing relationships rather than protect future ones. “My children don't need testing. I feel very strongly about this… the fear of it paralyzes them and doesn't let them create relationships.” (22) Strongly support preventive reproductive options for future generations; often advocate for current generation testing. “There are only advantages to this process in order to prevent consequences and continuity of the disease.” (34) “The Recommendation Paradox” across groups. Often advocate for knowledge based on their experience. “It's better to know in order to prepare for the future.” (13) Valuing prevention for offspring in retrospect, while simultaneously choosing not to know their own genetic status “If I were before childbirth, maybe I would do PGT‐M, but I would prefer not to know about myself.” (38) Generally, seek knowledge to aid in planning and care. “Uncertainty consumes a lot of unnecessary energy. It's better to know and treat.” (9) Often feel a strong responsibility to prevent HD in future generations. “I'm a carrier and I had children through egg donation. If we can stop the disease, that's the most important thing!” (35) May struggle between personal desire not to know and family planning. “It's worth it for those who don't have children to do the test to prevent it for the next generation… For those who already have children—it introduces unnecessary pressure.” (23) Often prioritize family planning and prevention. “To stop the chain! Enough with this disease! To take responsibility for the family, for the children!” (27) May emphasize practical benefits based on their experience. “If the result is positive, the person can be aware of the progression of symptoms and follow developments and medications for the disease.” (10) Often most conflicted about the emotional burden of knowing. “What's the benefit? To live with knowing? There's no cure, what will it give? I know that a high percent of patients commit suicide. How can that be stopped?” (24) May focus on practical benefits for care and planning. “When you know there's a disease, and the person is living their life, it's better not to get into stress.” (11) Strongly support preventive reproductive options for future generations; may have mixed feelings about current generation testing. “I would encourage everyone to receive treatment on time and to have children after genetic testing of the embryo/fetus.” (4) *In Hebrew, the word for fetus and embryo is the same Some support preventive reproductive options for future generations, while others prioritize present emotional wellbeing over future genetic prevention, fearing that testing would harm existing relationships rather than protect future ones. “My children don't need testing. I feel very strongly about this… the fear of it paralyzes them and doesn't let them create relationships.” (22) Strongly support preventive reproductive options for future generations; often advocate for current generation testing. “There are only advantages to this process in order to prevent consequences and continuity of the disease.” (34) This table illustrates the complex and sometimes contradictory attitudes toward genetic testing and reproductive options among different affected individuals and family members in the HD community. While most groups express support for preventive reproductive options for future generations, attitudes vary by group and individual circumstance, reflecting the core tension of the recommendation paradox. For example, interviewee 22 illustrates a nuanced position: the participant, herself at‐risk, is not opposing prevention for future generations but rather expresses a wish to protect her children, who are also at‐risk, from the psychological burden of predictive testing and its potential impact on their relationships and life choices. This highlights the paradox: resistance to current‐generation predictive testing coexisting with broader support for preventing HD transmission in offspring. Discussion The findings reveal paradoxical and often consistent attitudes toward genetic testing, disclosure, and reproductive choices among individuals affected by HD and their families. Surprised by HD? Family members were often genuinely surprised by HD diagnoses despite the predictable genetic transmission. Multiple mechanisms may underly this pattern of nondisclosure and surprise. Families may have lacked understanding of HD's genetic transmission, particularly if the condition was misdiagnosed or misattributed to other neurological disorders (as in Participant 16's case, where HD was called “Parkinson's or dementia”). Alternatively, some families may have intentionally concealed the diagnosis due to fear of social stigma, concern about impacts on marriage prospects (as explicitly stated by Participant 14's family), or denial of the condition's hereditary nature. In some cases, older generations may have died before accurate HD diagnosis was available, leaving younger family members unaware of their genetic risk (Participant 44). The experiences shared by participants illustrate the profound impact of “at‐risk unawareness” on reproductive choices. This finding corresponds with previous work on family communication in HD (Cooper et al. 2024; Wilson et al. 2004), by highlighting the long‐term consequences of secrecy, barriers to communication, misinformation, feelings of shame and fear of judgment, sometimes resulting in the absence of internal familial and external social support. Our data does not permit determination of which mechanisms operated in each family's case, and likely multiple factors interact. However, the consistency of the “surprise” experience across participants, despite HD's well‐established genetic pattern, suggests that information flow about genetic risk within families is complex and often disrupted. This finding underscores the importance of healthcare providers' awareness of the potential for hidden or misunderstood diagnoses and highlights the need to provide additional support and education to newly diagnosed individuals and their families. Truth, Luck, and Autonomy: Unpacking Genetic Testing Choices in a Fully Funded Healthcare System The “Truth or luck” theme reveals a stark division in attitudes toward predictive testing, echoing the ongoing debate in the literature about the benefits and risks of early knowledge of HD status. This division is historically evident in the review by Crozier et al. (2015), who highlight a striking discrepancy: while initial surveys showed 56%–81% of at‐risk individuals expressing desire for testing, actual uptake rates after testing became available were dramatically lower at only 20%. This gap reflects psychological dynamics involved in this decision‐making process. Perhaps unsurprisingly, we revealed strong reservations about testing, with some participants expressing concerns about the psychological burden of knowing one's status in the absence of a cure. This tension reflects the profound ambivalence that characterizes predictive testing decisions in HD, as described by Anderson et al. (2019), who queried 733 individuals who chose not to undergo genetic testing while participating in a prospective Huntington at‐risk observational study (PHAROS), between 1999 and 2008. The temporal dimensions explored by Wieringa et al. (2022) and Cooper et al. (2025) provide additional context for understanding divergent testing attitudes. Cooper et al.'s finding that at‐risk individuals experience “managing the possibility of a time‐limited lifespan”, with pressure to accomplish life goals before potential symptom onset, resonates with our participants' emphasis on “living in the present” versus “preparing for the future.” Interviewees in our study who chose to avoid testing may be, in part, attempting to escape this heightened temporal awareness. Conversely, those seeking testing may be embracing the opportunity to “make the most of time” through informed planning and reproductive decision‐making, even if that knowledge comes with psychological burdens. These psychological and social factors are evident in the contrasting perspectives we found across different groups, demonstrating how personal experience and position within the family system shape attitudes toward testing and reproductive choices. These findings build on previous work on family dynamics in HD (Cooper et al. 2024; Vamos et al. 2007). The tendency for PWHD to advocate for family planning based on their experiences, while at‐risk individuals often prefer uncertainty about their own status, reflects how one's position within the family system fundamentally shapes the relationship between personal testing decisions and recommendations for others—the core tension underlying the recommendation paradox. In healthcare systems where both genetic testing and reproductive options are fully or partially funded, such as Belgium, France, the Netherlands, England, and Israel, cost alone cannot explain low uptake. Our findings confirm that psychological factors remained the primary determinants of testing decisions regardless of financial accessibility. These findings suggest that just as advanced healthcare directives and planning of end of life have become legitimate and frequent topics in the clinical setting, family planning should be discussed, allowing autonomous decision making based on updated knowledge of options. This approach would normalize these crucial conversations and empower individuals and families affected by HD. The complex interplay between individual autonomy and societal implications has been explored across multiple domains including bioethics, law, and social policy (Dupras et al. 2022; Kemper et al. 2019; Sobel and Cowan 2000; Valdés 2023). Central to this discussion should be the voices and experiences of those at‐risk and those confronting HD's daily challenges. Their perspectives underscore that access to reproductive options empowers individuals to make informed choices about their future. This is consistent with recent ethical frameworks supporting unrestricted access to noninvasive prenatal testing for adult‐onset conditions as an expression of reproductive autonomy (Marks et al. 2024). The Paradox in Reproductive Decision‐Making The “Recommendation paradox” identified in our study extends the historical pattern of low reproductive technology uptake despite strong expressed support (Kessler et al. 1987; Schulman and Stern 2015). We identified a systematic paradox where the same individuals hold genuinely divergent attitudes toward testing for themselves versus their offspring, not as contradictory beliefs, but as coherent positions shaped by their relationship to HD. The paradox emerged through tensions between personal autonomy and family responsibility, knowledge and uncertainty, emotional burden and practical benefits. These tensions manifested differently depending on whether participants were living with HD, at‐risk, or caring for affected relatives. This paradox persisted in a fully funded healthcare system, demonstrating that removing economic barriers does not resolve the underlying psychological tensions. Identifying “the recommendation paradox” as a specific phenomenon builds upon and extends previous literature on HD reproductive decision‐making. Klitzman et al. (2007) identified important differences between personal testing attitudes and reproductive choices; our study complements this work by examining how these attitudes vary systematically across family member roles—living with HD, at‐risk relatives, and caregivers. Pierron et al.'s (2021) finding that testing motivations oscillate between “preventing transmission” and “personal right to know” across time periods resonates with our observation that individuals may hold both orientations simultaneously, weighted differently depending on whether they are considering testing for themselves or preventing transmission to children. Fahy et al.'s (2023) systematic review identified five key themes in HD reproductive decision‐making (risk perception, technology views, decisional complexity, child welfare, and support needs); our paradox offers a window into the mechanisms underlying this complexity, revealing how competing values and concerns coexist within individuals and families. Our study's setting within a fully funded healthcare system adds an important dimension to this literature, demonstrating that these psychological patterns persist independent of economic constraints and suggesting that financial accessibility, while important, addresses only one dimension of reproductive decision‐making barriers. Despite strong verbal endorsement of PGT‐M during genetic counseling sessions, actual utilization remains modest. Among the at‐risk relatives in our sample, only a minority (only 2 couples, as far as we know) had pursued PGT‐M, consistent with uptake rates documented in the literature (Van Rij et al. 2014; Piña‐Aguilar et al. 2019). This suggests that the recommendation paradox is not merely a theoretical stance but is reflected in actual behavior. It should be noted that the Israeli cultural context may influence attitudes toward reproductive technologies and genetic testing in several ways. Israel has one of the world's most extensive in vitro fertilization (IVF) systems (Shenhav‐Goldberg et al. 2019). Additionally, Jewish cultural traditions emphasize intergenerational responsibility (Hashiloni‐Dolev 2018), which may further shape attitudes toward preventing genetic disease transmission. However, we also observed the ‘recommendation paradox’ wherein individuals endorsed PGT‐M for offspring while avoiding personal testing, a pattern documented across multiple cultural contexts, suggesting that while absolute uptake rates may vary culturally, the underlying psychological tensions may be more universal. Future cross‐cultural research could clarify which aspects of reproductive decision‐making in HD are culturally specific versus shared across population. Future research employing mixed methods could quantitatively track the relationship between expressed attitudes and subsequent reproductive choices within the same cohort, helping to clarify whether the paradox represents temporal evolution of attitudes or persistent ambivalence. Implications for Practice The issues of nondisclosure within families, the right not to know, and the potential for PGT‐M to prevent HD in future generations all raise complex ethical questions that reflect ongoing debates in the literature (Marks et al. 2024; Roberts et al. 2020). The strong support for PGT‐M among our participants, even those hesitant about personal testing, creates a discussion on the potential of a new form of genetic responsibility. While this approach may lead to reduced incidence of HD in future generations, it also risks creating pressure on at‐risk individuals to use PGT‐M, potentially infringing on reproductive autonomy. These ethical considerations have direct implications for genetic counseling practices. Counselors must navigate personal autonomy, family dynamics, and societal expectations while providing accurate information and support. We suggest explicitly exploring whether individuals feel differently about genetic testing for themselves versus their children, creating space to discuss paradoxes, if present, without judgment and help families navigate complex, sometimes contradictory feelings. In other words, our findings suggest a need for more nuanced guidelines that can accommodate the diverse and sometimes contradictory attitudes within HD families. International guidelines for HD treatment emphasize multidisciplinary care (Bachoud‐Lévi et al. 2019), and guidelines for predictive genetic testing already emphasize exploring reproductive options (MacLeod et al. 2013); our findings suggest counselors should go further by explicitly addressing the potential divergence between individuals' attitudes toward testing for themselves versus preventing transmission to offspring. Since the completion of our data collection in 2024, the HD treatment landscape has shifted. In September 2025, preliminary results from the first gene therapy trial showed statistically significant slowing of disease progression (uniQure 2025), representing a potential breakthrough. This might signal a fundamental change in the calculus of genetic testing. Many of our participants expressed reluctance toward predictive testing because “there's no cure, what will it give?” The emergence of potentially disease‐modifying therapies may alter this risk–benefit analysis, making early knowledge of genetic status more valuable for accessing future treatments. Limitations, Methodological Reflections and Future Directions Qualitative coding was conducted primarily by a single researcher (first author), which may introduce individual interpretive bias despite efforts to maintain reflexivity. Also, the professional relationship between the researcher conducting the interviews and the study participants may have introduced bias in some instances, while also fostering a supportive environment for open sharing of experiences. Future research employing multiple independent coders could strengthen analytical reliability through formal inter‐rater reliability assessment. While we identified three main themes through systematic analysis, alternative thematic structures may exist within the data. Our framework represents one interpretive approach among several possibilities. The decision to organize Theme 3 using four analytical dimensions (Table 2) reflects our interpretive lens and may not capture all relevant patterns in participant responses. The study's focus on the Israeli context provides a unique perspective on HD management in a system with fully funded genetic services. However, this specificity also limits the generalizability of our findings. Future research could compare these results with similar studies in different healthcare systems to better understand the impact of funding and accessibility on attitudes toward genetic testing and PGT‐M in HD. While participants discussed various reproductive options, we did not systematically distinguish between attitudes toward prenatal testing versus PGT‐M, which may involve different ethical considerations. Future research could explore whether the recommendation paradox manifests differently across these reproductive technologies. Additionally, while parenting status was documented, we did not systematically examine whether having existing biological children influenced attitudes toward PGT‐M, which may be a relevant variable for future investigation. All participants were recruited from a single HD clinic in Israel, which may introduce selection bias. The sample represents individuals who have already accessed specialized HD care and may be more informed about genetic testing options than the broader at‐risk population. Conclusion This qualitative study of 51 HD family members identified a recommendation paradox: individuals often endorse predictive testing and reproductive options for offspring while avoiding or regretting personal predictive testing. This paradox was revealed in a fully funded healthcare system, demonstrating that psychological barriers remain, even when economic constraints are removed. The paradox creates ethical tensions between reproductive autonomy and emerging expectations around genetic responsibility. In our view, counseling should address the diverse and sometimes conflicting attitudes within HD families, recognizing that people with HD, at‐risk relatives, and caregivers may view testing and reproductive decisions through different lenses shaped by their position in the family system. Author Contributions Noit Inbar made substantial contributions to the conception and design of the work, and to the acquisition, analysis, and interpretation of data for the work; drafted and reviewed the work critically for important intellectual content; approved the final version to be published; and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Aya Bar David made substantial contributions to the conception and design of the work, and to the acquisition, analysis, and interpretation of data for the work; reviewed the work critically for important intellectual content; approved the final version to be published; and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Achinoam Socher, Penina Ponger, Nurit Omer, Adi Reches, Yael Manor, and Tanya Gurevich each made substantial contributions to the conception and design of the work and to the interpretation of data for the work; reviewed the work critically for important intellectual content; approved the final version to be published; and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Funding The authors have no funding to report. Ethics Statement This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Institutional Review Board of Tel Aviv Sourasky Medical Center (IRB approval number: 0614‐18). Consent Written informed consent was obtained from all participants prior to their inclusion in the study. No identifying information is included in the manuscript. Conflicts of Interest The authors declare no conflicts of interest.